Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CNR2 | P34972 | 11/20 | 0.60 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14068257 | 0.85 | TAS2R14 (0.63) | TAS2R14MEN1KMT2ACNR2CXCR3 | |
| SCHEMBL984791 | 0.85 | TAS2R14 (0.71) | TAS2R14MEN1KMT2ACNR2CXCR3 | |
| SCHEMBL4243334 | 0.84 | BACE1 (0.71) | TAS2R14MEN1KMT2ACNR2CXCR3 | |
| SCHEMBL4917430 | 0.83 | CNR2 (0.68) | TAS2R14MEN1KMT2ACNR2CNR1 | |
| SCHEMBL4741416 | 0.81 | TAS2R14 (0.62) | TAS2R14MEN1KMT2ACNR2CXCR3 | |
| SCHEMBL14025440 | 0.81 | ALDH1A1 (0.56) | TAS2R14MEN1KMT2ACNR2CNR1 | |
| SCHEMBL4413527 | 0.81 | HTR2A (0.75) | TAS2R14MEN1KMT2ACNR2CXCR3 | |
| SCHEMBL8911635 | 0.81 | TAS2R14 (0.78) | TAS2R14MEN1KMT2ACNR2CNR1 | |
| SCHEMBL10929983 | 0.81 | SERPINE1 (0.51) | TAS2R14CNR2MAPT | |
| SCHEMBL1278788 | 0.80 | TAS2R14 (0.97) | TAS2R14MEN1KMT2ACXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013130943-A1 | ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES | GENENTECH, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | TAS2R14 4808/4885MEN1 173/4885KMT2A 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.